Oscar Health’s Stock Gets a Second Look—What’s Behind the Buzz?

The Bull Case: Barclays Sees 25% Upside, But Why?

In a bold move, Barclays just handed Oscar Health a glowing endorsement—upgrading its stock to "Overweight" with a $35 price target, implying a potential 25% surge in share value. The timing couldn’t be better (or riskier): Oscar’s stock has already soared 160% since March, leaving investors to wonder—how much higher can it go?

Barclays’ optimism stems from a striking valuation gap. While competitors trade at high earnings multiples, Oscar languishes at just 11.5 times earnings—a discrepancy that could correct itself if investors finally recognize the Affordable Care Act (ACA) market’s untapped potential. Adding fuel to the fire, 88% of analysts have issued a "Buy" rating, reinforcing the bullish sentiment.

The Bear Case: Cracks in the Foundation?

Not everyone’s drinking the Kool-Aid. Skeptics argue that Oscar’s stock could dip in the next year, despite Barclays’ long-term bullishness. Wall Street’s average price target sits at $22—a 20% haircut from current levels. And unlike traditional insurers, Oscar pays no dividends, stripping away a key incentive for long-term holders.

The Growth Gamble: Can Oscar Deliver?

The ultimate question: Can Oscar sustain its momentum? Barclays thinks Wall Street’s 2028 profit forecasts are too conservative, with Oscar targeting 5% margins while analysts project just 3%. If the company meets its own lofty goals—and early trends suggest the market is improving—shares could explode higher.

Yet, the mixed signals mean Oscar isn’t a surefire bet. Some see blue-sky potential, while others warn of short-term volatility. The verdict? Time—and Oscar’s execution—will decide.